Beyond Air, Inc. — Form 8-K
Filed October 8, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Beyond Air reported preliminary Q3 2026 revenue of $2.3 million, representing 30% sequential growth and 27% year-over-year growth, driven by continued LungFit PH adoption. The company reaffirmed $8 million CY2026 guidance and $16–$18 million CY2027 guidance (the latter contingent on FDA approval of the second-generation system, which remains under review). All figures are preliminary and unaudited.
Why this rating
Strong sequential/YoY growth and highest quarterly revenue is good news; however, relative to $15.5M market cap, Q3 run rate (~$9.2M annualized) approaches but does not exceed guidance. Material for a micro-cap but depends critically on second-gen FDA approval risk.
See more from October 8, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.